Growth inhibition of human vascular smooth muscle cells by fenofibrate: a possible therapy for restenosis.
OBJECTIVE
The aim was to assess the growth inhibitory effect of fibrates on human vascular smooth muscle cells. Restenosis is the most important factor limiting the long term success of invasive vascular interventions and there is as yet no effective preventive treatment. Platelet derived growth factor (PDGF) is considered to be an important growth promoting agent for vascular smooth muscle cells (VSMC) and fenofibric acid (a hypolipidaemic drug) has been reported to be a PDGF antagonist.


METHODS
The effect of the fibrate drugs fenofibrate, clofibrate, bezafibrate, and gemfibrozil were examined on the proliferation of cultured human vascular smooth muscle cells derived from saphenous vein (n = 20) and graft stenoses (n = 7).


RESULTS
Fenofibrate (100 microM) produced potent inhibition (48%) of VSMC proliferation at a concentration equivalent to that of its circulating metabolite fenofibric acid, but none of the other drugs produced any significant effect on growth. VSMC derived from graft stenoses were equally sensitive to inhibition as saphenous vein derived controls, in contrast to our previous work which reported that graft stenosis derived VSMC were resistant to growth inhibition by the physiological inhibitor heparin. The antiproliferative effect of fenofibrate was independent of inhibition of cellular cholesterol synthesis or toxicity. Fenofibrate inhibited VSMC growth induced by 15% fetal calf serum, PDGF, and basic fibroblast growth factor to a similar degree, indicating that it is not a specific PDGF antagonist.


CONCLUSIONS
Fenofibrate is not a specific PDGF antagonist. Fenofibric acid, one of the principal metabolites of fenofibrate, did not produce any inhibition of growth, suggesting that oral administration of fenofibrate would not be efficacious. Fenofibrate is the first potent inhibitor to be described for VSMC derived from human myo-intimal hyperplastic lesions.
Department of Clinical Pharmacology, St Mary's Hospital and Medical School, London, United Kingdom.
E
E
Munro
M
M
Patel
P
P
Chan
L
L
Betteridge
K
K
Gallagher
M
M
Schachter
J
J
Wolfe
P
P
Sever
D001629:Bezafibrate / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002994:Clofibrate / Q000494:pharmacology; D011345:Fenofibrate / Q000031:analogs & derivatives / Q000494:pharmacology*; D015248:Gemfibrozil / Q000494:pharmacology; D006083:Graft Occlusion, Vascular / Q000473:pathology; D006801:Humans; D009130:Muscle, Smooth / Q000166:cytology / Q000187:drug effects*; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D012501:Saphenous Vein / Q000166:cytology
D010982:Platelet-Derived Growth Factor; C006012:fenofibric acid; D002994:Clofibrate; D015248:Gemfibrozil; D011345:Fenofibrate; D001629:Bezafibrate